Medifast, Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. The filing also reports fourth-quarter results. Medifast sells weight-management and wellness products, primarily through its OPTA VIA coaching and direct-sales model. Beginning in 2018, it reported as one operating segment; OPTA VIA generated 92.9% of annual revenue.
Financial performance
| Metric | FY 2018 | FY 2017 | Change |
|---|---|---|---|
| Revenue | $501.0 million | $301.6 million | +66.1% |
| Gross profit / margin | $379.9 million / 75.8% | $227.8 million / 75.5% | Margin +0.3 percentage points |
| Operating income / margin | $69.1 million / 13.8% | $39.6 million / 13.1% | Operating income +74.3% |
| Net income | $55.8 million | $27.7 million | +101.3% |
| Diluted EPS | $4.62 | $2.29 | — |
| Operating cash flow | $60.8 million | $43.2 million | +$17.6 million |
Fourth-quarter revenue was $145.8 million versus $78.0 million in Q4 2017; net income was $15.7 million versus $7.3 million, and diluted EPS was $1.30 versus $0.60. Annual operating cash flow benefited from higher earnings but was partly offset by increased inventory investment. Investing activities used $1.2 million; financing activities used $53.3 million, including $30.0 million of stock repurchases and $23.2 million of dividends paid.
At year-end, cash and cash equivalents were $81.4 million and investment securities were $19.7 million, totaling approximately $101.0 million. Working capital was $85.2 million, down from $88.1 million. The company reported no debt. Total assets were $169.4 million and stockholders’ equity was $109.1 million.
Material changes and drivers
- Growth was driven by OPTA VIA Coach expansion and higher quarterly revenue per earning Coach. At December 31, there were 24,100 active earning Coaches, up 60.7% year over year; quarterly revenue per Coach was $5,756, up 26.2%.
- Gross margin rose modestly, partly due to favorable manufacturing absorption from higher production volumes and inventory buildup. Management said this benefit was expected to be temporary as inventory normalized.
- SG&A increased 65.2% to $310.8 million, mainly reflecting higher OPTA VIA commissions. Commission expense as a share of revenue increased to 39.6% from 35.6%, while other expenses leveraged against higher sales.
- The effective tax rate fell to 20.9% from 31.3%, primarily reflecting the lower federal statutory rate under the Tax Cuts and Jobs Act, partly offset by the elimination of the Domestic Manufacturer Deduction.
- Adoption of ASC 606 reduced opening 2018 retained earnings by $2.0 million. The filing’s 2018 comparison indicates adoption increased reported revenue by $1.8 million and net income by $0.2 million relative to the prior accounting treatment.
Outlook, risks and contingencies
- Management anticipated a 2019 full-year tax rate of 22.5%–23.5%. The filing provides no specific revenue or earnings guidance.
- Medifast planned to launch in Hong Kong and Singapore in the first half of 2019, following approximately $5 million of 2018 market preparation. Its stated objective was to scale the markets to profitability and fund expansion without negatively affecting domestic operating margins.
- Key risks include Coach retention and growth; regulatory scrutiny of direct selling, compensation practices, and advertising claims; product liability and health-related claims; competition and changing consumer preferences; supply-chain reliance on third parties and the company’s single manufacturing facility; cybersecurity; and risks of international expansion, including compliance and currency exposure.
- Ordinary-course litigation was not expected by management to have a material adverse effect, though outcomes are uncertain. Contractual obligations included $9.5 million of operating lease payments and $10.1 million of unconditional purchase obligations.
- The company declared $2.19 per share in dividends during 2018 and repurchased $30.0 million of stock. Management expressed intent to continue dividends but gave no assurance of future declarations or payments. Auditors issued unqualified opinions on the financial statements and internal controls; management also reported effective controls.
Investor verification priorities
- Confirm that Coach growth, productivity, and client acquisition can be sustained, and assess dependence on the OPTA VIA channel.
- Track inventory levels and cash conversion, especially given the temporary manufacturing-absorption benefit and the substantial 2018 inventory increase.
- Review commission economics and whether expense growth remains aligned with sales growth as the Coach network expands.
- Monitor Hong Kong and Singapore launch spending, profitability, regulatory compliance, and any effect on domestic margins.
- Verify subsequent dividend and repurchase activity, liquidity needs, and the effect of lease-liability recognition under the new lease standard.